Lipella Pharmaceuticals (NASDAQ: LIPO) announced that on June 10, 2025 the U.S. Patent and Trademark Office (USPTO) issued Patent No. 12,326,492, titled Systems and Methods of Detecting Interstitial Cystitis, providing protection for its diagnostic technology through 2045—subject to potential extensions.
The patent covers a method, using MRI, to detect lesions (or permeability defects) in body cavities. “This method can potentially provide enhanced outcome assessments to our development programs; especially mucosal disorders, including our existing programs: LP-310 for oral lichen planus, LP-10 for hemorrhagic cystitis, and LP-50 for bladder cancer,” said Dr. Michael Chancellor, CMO of Lipella.
Jonathan Kaufman, CEO of Lipella, commented, “This patent strengthens Lipella’s strategic position in drug delivery. The ability to non-invasively monitor the progression (or regression) of body cavity lesions, using a novel MRI contrast agent, will not only enhance our existing clinical development efforts, but can itself become a clinically-relevant early detection tool.”
